Hook & thesis
AngioDynamics (ANGO) is growing: the company reported better-than-expected top-line prints and management has been raising guidance. Yet the stock is trading lower after a leadership surprise and intermittent profitability, creating short-term noise that the market is punishing. That dislocation creates a defined-entry opportunity for disciplined traders who want exposure to a med-tech recovery without buying right before another downleg.
Our thesis is simple: med-tech end-markets are supportive, AngioDynamics has visible growth engines (Med Tech segment and oncology products), and valuation metrics - a market cap near $425 million and an enterprise value around $387 million - imply upside if execution stays intact. But the pathway to consistent profitability is still in progress, free cash flow is modest, and management transition risk increases headline volatility. We recommend a mid-term swing trade sized to risk tolerance with a clear entry, stop and target.
What the company does and why the market should care
AngioDynamics manufactures and sells devices used in vascular access, peripheral vascular disease, surgery and oncology. Its business is split between a Med Tech segment (including thrombus-management platform Auryon and NanoKnife technologies) and a Med Device segment focused on high-volume core products like ports and venous devices. Investors should care because these product categories benefit from secular shifts toward minimally invasive care and outpatient procedures, and the company has been posting double-digit sales growth in key quarters.
Recent headlines have amplified investor sensitivity: the stock fell sharply after management announced a CEO retirement, even though the company beat on a recent quarterly revenue print of $79.4 million and raised 2026 guidance. That reaction highlights two things: first, the underlying business is gaining traction; second, leadership uncertainty is a catalyst for outsized short-term moves. Traders can use that volatility to establish a favorable risk/reward.
Key financial and market readouts
- Market cap: approximately $424.7 million; enterprise value: about $387.1 million.
- Price metrics: price-to-sales ~1.35, EV-to-sales ~1.23 and price-to-book roughly 2.45. Trailing earnings are negative (EPS -$0.76; P/E is negative), reflecting the company is not consistently profitable yet.
- Cash flow: free cash flow was reported at $2.86 million, small relative to EV and market cap.
- Shares and liquidity: ~41.2 million shares outstanding; float ~36.45 million. Average daily volume is roughly 397k, though recent sessions have seen elevated activity (today's volume ~1.23M), making the name tradeable on spikes.
- Technicals: recent price action has pushed the stock below short-term averages (10/20/50-day SMAs around $10.84-$10.96), RSI sits in the low 40s (42.6), and the MACD shows a modest bullish histogram—signs of mixed momentum but not a full breakdown.
- Short interest and mechanics: recent short interest readings show more than 1.7 million shares short with days-to-cover rising in some settlement windows (6.3 days on 03/13/2026). Short-volume prints have been material in recent sessions (on 04/02 short volume was ~236k of total 483k), which can amplify moves both ways.
Valuation framing
At roughly $425 million market capitalization, AngioDynamics sits in a valuation band that already reflects growth but not full profitability. Price-to-sales around 1.35 and EV-to-sales near 1.23 are not demanding compared with high-growth med-tech peers, but the small free cash flow ($2.86 million) and negative EPS keep multiples muted. In short, the market is willing to pay for revenue growth but is waiting for consistent margin improvement and clearer leadership before re-rating to higher multiples.
| Metric | Value |
|---|---|
| Market cap | $424.7M |
| Enterprise value | $387.1M |
| Price-to-sales | 1.35 |
| EV-to-sales | 1.23 |
| Free cash flow | $2.86M |
| EPS (TTM) | -$0.76 |
Catalysts to watch (2-5)
- Management succession announcement - a credible external hire or clear internal plan would reduce headline risk and likely stem volatility.
- Quarterly results that confirm margin progress or larger free cash flow generation - that would support a re-rating from P/S multiples to earnings-based multiples.
- Stronger adoption of Auryon and NanoKnife in core hospital systems or new reimbursement wins that expand procedure economics.
- Analyst coverage upgrades or higher price targets; historically firms have raised targets on strong execution (example: a prior raise to $13.00), which can move sentiment.
Trade plan - actionable and specific
We recommend a tactical long position with a mid-term horizon: enter at $10.305, stop out at $9.00 and target $13.00. This is a mid-term (45 trading days) swing trade sized as a portion of your overall risk budget. The thesis is that leadership noise and forced selling have created a measurable entry below near-term moving averages, but the business still has fundamental upside that can re-rate the multiple if the CEO transition is handled cleanly and results remain consistent.
Why these levels?
- Entry $10.305: this is the current market level where panic and headline selling has pulled the share price below recent short-term averages, giving a favorable risk entry.
- Stop $9.00: the $9 area is close to the recent 52-week low zone ($8.36) and would indicate the move is not a temporary headline-driven dip but a deeper conviction break; cutting risk here preserves capital.
- Target $13.00: represents a realistic reflation toward the 52-week high ($13.99) and is consistent with prior analyst targets and the company's revenue trajectory. Hitting $13 would materially tighten EV/S and begin to price in stronger margin expectations.
Timeframe rationale: mid-term (45 trading days). Leadership announcements, initial market reaction, and next quarterly cadence typically resolve within a 6- to 10-week window. That gives enough time for a hiring update, preliminary stabilization, or confirmation of guidance versus a shorter 10-day snap-back that could fizzle if the replacement story drags.
Risk profile and trade sizing
This trade is medium risk. The stop is modest relative to the entry (about $1.305 of downside); position size should be set so that a stop-triggered loss is within your pre-determined risk tolerance (e.g., 1-2% of portfolio). Expect elevated intraday volatility—recent short-volume prints and higher-than-normal volumes show this name can gap on news.
Risks & counterarguments
- Leadership uncertainty: The announced CEO retirement can extend into a prolonged search or a poor successor hire, creating sustained investor skepticism and operational disruption.
- Profitability timeline: The company still posts negative EPS (approx -$0.76) and small free cash flow ($2.86M). If margins don't improve, multiples will stay compressed and revenue growth alone may not lift the stock materially.
- Short-squeeze volatility: Elevated short interest and heavy short-volume days can cause whipsaws in either direction, increasing the likelihood of stop hits on intraday moves.
- Execution risk in commercial adoption: Growth depends on adoption of newer platforms and penetration of oncology and thrombus-management devices. Slower-than-expected adoption or reimbursement headwinds would hurt results.
- Macro/procedural risk: Any drop in procedure volumes or hospital purchasing restraint could hit revenue and delay margin expansion.
Counterargument: One could argue the market is right to be cautious: despite good revenue beats, the company is years away from consistent profitability and free cash flow is tiny relative to market cap, so the stock could trade sideways or lower until margins visibly improve. That perspective is valid and is why this trade uses a tight stop and a mid-term horizon rather than a buy-and-hold posture.
Conclusion & what would change our mind
We view AngioDynamics as a constructive but noisy growth story. The combination of real revenue momentum and a non-demanding P/S ratio supports a tactical long, but only with disciplined risk control. Our trade is a mid-term swing: enter $10.305, stop $9.00, target $13.00, plan to hold up to 45 trading days for leadership clarity and operational confirmation.
What would change our mind: grant conviction would increase if the company announces a credible CEO succession plan and the next quarterly results show both revenue growth and meaningful margin improvement or faster free cash flow generation. Conversely, a prolonged executive vacuum, a failure to convert guidance into results, or a big downward revision to procedure volumes would cause us to flip to a neutral/short stance.
Actionable trade: Long ANGO at $10.305, stop $9.00, target $13.00 - mid-term (45 trading days), medium risk.